$77.99
-0.19-0.24%
At Close: -
$78.24
0.250.32%
After Hours: 5:31 PM EDT
15 minutes delayed
AstraZeneca
AZNNASDAQ
AstraZeneca (NASDAQ:AZN) Stock, Analyst Ratings, Price Targets, Predictions
AstraZeneca PLC has a consensus price target of $45.73, established from looking at the 25 latest analyst ratings. The last 3 analyst ratings were released from Argus Research, Goldman Sachs, and BMO Capital on May 30, 2024, May 30, 2024, and April 26, 2024. With an average price target of $88 between Argus Research, Goldman Sachs, and BMO Capital, there's an implied 12.47% upside for AstraZeneca PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Argus Research
Goldman Sachs
BMO Capital
Deutsche Bank
Deutsche Bank
1calculated from analyst ratings
Analyst Ratings for AstraZeneca
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/30/2024 | Buy Now | 8.64% | Argus Research | Jasper Hellweg | $80 → $85 | Maintains | Buy | Get Alert |
| 05/30/2024 | Buy Now | 23.98% | Goldman Sachs | Rajan Sharma | → $97 | Initiates | → Buy | Get Alert |
| 04/26/2024 | Buy Now | 4.81% | BMO Capital | Etzer Darout | $80 → $82 | Maintains | Outperform | Get Alert |
| 04/16/2024 | Buy Now | — | Deutsche Bank | Emmanuel Papada | — | Upgrade | Sell → Hold | Get Alert |
| 02/12/2024 | Buy Now | 2.25% | BMO Capital | Etzer Darout | $82 → $80 | Maintains | Outperform | Get Alert |
| 02/08/2024 | Buy Now | — | Deutsche Bank | Emmanuel Papadakis | — | Downgrade | Buy → Hold | Get Alert |
| 01/23/2024 | Buy Now | 8.64% | Morgan Stanley | Mark Purcell | → $85 | Initiates | → Overweight | Get Alert |
| 01/03/2024 | Buy Now | — | Jefferies | Peter Welford | — | Downgrade | Buy → Hold | Get Alert |
| 09/25/2023 | Buy Now | 2.25% | Jefferies | Peter Welford | $66.5 → $80 | Upgrade | Hold → Buy | Get Alert |
| 09/08/2023 | Buy Now | — | Erste Group | — | — | Downgrade | Buy → Hold | Get Alert |
| 08/01/2023 | Buy Now | 6.08% | BMO Capital | Etzer Darout | $81 → $83 | Maintains | Outperform | Get Alert |
| 05/26/2023 | Buy Now | 2.25% | Argus Research | Jasper Hellweg | $85 → $80 | Maintains | Buy | Get Alert |
| 04/13/2023 | Buy Now | 8.64% | Argus Research | Jasper Hellweg | $75 → $85 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 4.81% | BMO Capital | Etzer Darout | → $82 | Initiates | → Outperform | Get Alert |
| 11/14/2022 | Buy Now | 0.97% | SVB Leerink | Andrew Berens | $78 → $79 | Maintains | Outperform | Get Alert |
| 11/11/2022 | Buy Now | -0.31% | SVB Leerink | Andrew Berens | $75 → $78 | Maintains | Outperform | Get Alert |
| 08/29/2022 | Buy Now | -4.14% | Argus Research | John Eade | → $75 | Upgrade | Hold → Buy | Get Alert |
| 05/04/2022 | Buy Now | -4.14% | SVB Leerink | Andrew Berens | $70 → $75 | Maintains | Outperform | Get Alert |
| 02/24/2022 | Buy Now | -10.53% | SVB Leerink | Andrew Berens | $65 → $70 | Maintains | Outperform | Get Alert |
| 02/11/2022 | Buy Now | — | DZ Bank | Elmar Kraus | — | Upgrade | Sell → Hold | Get Alert |
| 12/07/2021 | Buy Now | — | Jefferies | Peter Welford | — | Downgrade | Buy → Hold | Get Alert |
| 09/27/2021 | Buy Now | -6.7% | SVB Leerink | Andrew Berens | — | Maintains | Outperform | Get Alert |
| 09/20/2021 | Buy Now | -9.25% | SVB Leerink | Andrew Berens | — | Maintains | Outperform | Get Alert |
| 08/04/2021 | Buy Now | -11.81% | SVB Leerink | Andrew Berens | — | Maintains | Outperform | Get Alert |
| 07/16/2021 | Buy Now | -19.48% | SVB Leerink | Andrew Berens | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for AstraZeneca (AZN) stock?
The latest price target for AstraZeneca (NASDAQ:AZN) was reported by Argus Research on May 30, 2024. The analyst firm set a price target for $85.00 expecting AZN to rise to within 12 months (a possible 8.64% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AstraZeneca (AZN)?
The latest analyst rating for AstraZeneca (NASDAQ:AZN) was provided by Argus Research, and AstraZeneca maintained their buy rating.
When was the last upgrade for AstraZeneca (AZN)?
The last upgrade for AstraZeneca PLC happened on April 16, 2024 when Deutsche Bank raised their price target to N/A. Deutsche Bank previously had a sell for AstraZeneca PLC.
When was the last downgrade for AstraZeneca (AZN)?
The last downgrade for AstraZeneca PLC happened on February 8, 2024 when Deutsche Bank changed their price target from N/A to N/A for AstraZeneca PLC.
When is the next analyst rating going to be posted or updated for AstraZeneca (AZN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AstraZeneca, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AstraZeneca was filed on May 30, 2024 so you should expect the next rating to be made available sometime around May 30, 2025.
Is the Analyst Rating AstraZeneca (AZN) correct?
While ratings are subjective and will change, the latest AstraZeneca (AZN) rating was a maintained with a price target of $80.00 to $85.00. The current price AstraZeneca (AZN) is trading at is $78.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.